Residency · Residency · Hematology Thrombosis

Coagulation Cascade and Hemostasis Physiology

Introduction

Hemostasis is the physiologic process that arrests bleeding at sites of vascular injury while maintaining vascular patency throughout the remainder of the circulation. It is composed of three interconnected components: primary hemostasis, which forms the initial platelet plug; secondary hemostasis, which stabilizes that plug through the coagulation cascade and fibrin generation; and fibrinolysis, which limits clot propagation and eventually dissolves the clot once vascular repair is complete. The cell-based model of coagulation has largely supplanted the traditional cascade model as the framework for understanding in vivo hemostasis. A thorough understanding of normal hemostatic physiology is the prerequisite for diagnosing and treating both bleeding and thrombotic disorders.

Primary Hemostasis

Vascular Injury Response

When the vascular endothelium is disrupted, the subendothelial matrix is exposed, including collagen, tissue factor, and von Willebrand factor (VWF). Under normal conditions, the intact endothelium is actively antithrombotic: it produces prostacyclin (PGI2) and nitric oxide (NO), which inhibit platelet activation and promote vasodilation; it expresses thrombomodulin, which activates the protein C anticoagulant pathway; it displays heparan sulfate proteoglycans, which enhance antithrombin activity; and it produces tissue factor pathway inhibitor (TFPI), which limits the initiation of coagulation. Loss of these protective mechanisms upon endothelial disruption is itself a prothrombotic stimulus.

Platelet Adhesion

VWF serves as the critical molecular bridge between platelets and the subendothelial collagen matrix. The interaction between VWF and the platelet GPIb/IX/V receptor complex mediates initial platelet tethering, a process that is particularly important under the high shear stress conditions found in the arterial circulation. The collagen-GPVI interaction provides firm adhesion and initiates intracellular signaling cascades that lead to platelet activation. The collagen-GPIa/IIa receptor (integrin alpha-2-beta-1) provides an additional adhesion mechanism.

Platelet Activation

Upon activation, platelets undergo dramatic morphologic and functional changes, including shape change from a smooth discoid form to a spiculated sphere, granule secretion, and surface receptor expression. Multiple agonists drive platelet activation: thrombin, the most potent activator, signals through PAR-1 and PAR-4 protease-activated receptors; ADP acts through P2Y1 and P2Y12 receptors; thromboxane A2 (TXA2), collagen, and epinephrine each contribute through their respective receptor pathways.

Dense granule release delivers ADP, serotonin, calcium, and ATP into the local environment, recruiting additional platelets to the site of injury. Alpha granule release provides VWF, fibrinogen, factor V, platelet factor 4 (PF4), platelet-derived growth factor (PDGF), and P-selectin. Thromboxane A2 is synthesized via the cyclooxygenase-1 (COX-1) pathway and serves as a powerful amplifier of platelet activation; this is the target of aspirin's antiplatelet effect. A critically important event during platelet activation is the exposure of phosphatidylserine (PS) on the outer membrane leaflet, which provides the negatively charged procoagulant surface essential for the assembly of coagulation factor complexes during secondary hemostasis.

Platelet Aggregation

The GPIIb/IIIa integrin (alpha-IIb-beta-3) is the most abundant platelet surface receptor and is the final common pathway of platelet aggregation. Upon platelet activation, GPIIb/IIIa undergoes a conformational change that enables it to bind fibrinogen and VWF, cross-linking adjacent platelets into a growing aggregate. This receptor is the target of GPIIb/IIIa inhibitors including abciximab, eptifibatide, and tirofiban. The resulting primary hemostatic plug is sufficient for hemostasis in small vessels but requires reinforcement by the fibrin mesh generated through secondary hemostasis for larger vascular injuries.

<image>A detailed diagram of primary hemostasis in three sequential panels. Panel 1 (Adhesion): Show a cross-section of damaged blood vessel with exposed subendothelial collagen. VWF is shown binding to both collagen and platelet GPIb/IX/V receptor, with a separate GPVI-collagen interaction. Panel 2 (Activation): Show platelet shape change from disc to spiculated sphere, with granule release (dense granules releasing ADP and TXA2, alpha granules releasing VWF and fibrinogen). Depict signaling pathways: thrombin → PAR-1/4, ADP → P2Y12, TXA2 → TP receptor. Show phosphatidylserine flipping to the outer membrane. Panel 3 (Aggregation): Show multiple activated platelets cross-linked by fibrinogen molecules binding to GPIIb/IIIa receptors on adjacent platelets, forming the primary platelet plug. Include drug targets: aspirin blocking COX-1/TXA2, clopidogrel blocking P2Y12, abciximab blocking GPIIb/IIIa. Medical textbook illustration style with molecular detail.</image>

Secondary Hemostasis - Cell-Based Model of Coagulation

Initiation Phase (TF-Bearing Cell)

The initiation phase occurs on tissue factor-bearing cells, including subendothelial fibroblasts, smooth muscle cells, and, under pathologic conditions, activated monocytes and endothelium. Tissue factor binds factor VIIa, a small amount of which circulates constitutively in the blood (approximately 1% of total factor VII). The resulting TF-VIIa complex, known as the extrinsic tenase, activates factor X to Xa and factor IX to IXa. Factor Xa combines with factor Va to generate small initial amounts of thrombin, though this is not yet sufficient for the explosive thrombin burst required for effective hemostasis. TFPI rapidly inhibits the TF-VIIa-Xa complex, effectively limiting the initiation phase and preventing uncontrolled coagulation activation.

Amplification Phase (Platelet Surface)

The small amounts of thrombin generated during the initiation phase serve critical amplification functions. Thrombin activates platelets through PAR receptors, leading to phosphatidylserine exposure and the creation of a procoagulant surface. Thrombin activates factor V to Va on the platelet surface, activates factor VIII to VIIIa (releasing it from its carrier protein VWF), and activates factor XI to XIa. These events set the stage for the propagation phase by assembling the necessary cofactors and enzymes on the activated platelet surface.

Propagation Phase (Activated Platelet Surface)

Factor IXa, generated during the initiation phase, combines with factor VIIIa on the activated platelet surface to form the intrinsic tenase complex. This complex generates large quantities of factor Xa far more efficiently than the extrinsic tenase. Factor Xa then combines with factor Va on the platelet surface to form the prothrombinase complex, which converts prothrombin (factor II) to thrombin (factor IIa) in a massive thrombin burst. This thrombin burst cleaves fibrinogen to form fibrin monomers, which spontaneously polymerize to create the fibrin mesh. Factor XIIIa, activated by thrombin, cross-links adjacent fibrin strands through covalent bonds, converting the soluble fibrin polymer into a stable, insoluble clot resistant to mechanical disruption and premature fibrinolysis.

Traditional Cascade Correlation

While the cell-based model better represents in vivo coagulation, the traditional cascade framework remains clinically relevant for interpreting standard coagulation tests. The prothrombin time (PT) measures the extrinsic and common pathways, reflecting the function of factors VII, X, V, II, and fibrinogen. A prolonged PT is seen with warfarin therapy, vitamin K deficiency, liver disease, factor VII deficiency, and DIC. The INR (International Normalized Ratio) standardizes the PT using the International Sensitivity Index to allow comparison across laboratories and thromboplastin reagents.

The activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways, reflecting the function of factors XII, XI, IX, VIII, X, V, II, and fibrinogen. A prolonged aPTT is caused by heparin therapy, factor VIII or IX deficiency (hemophilia A and B), factor XI or XII deficiency, and lupus anticoagulant. The thrombin time (TT) specifically measures the conversion of fibrinogen to fibrin and is prolonged by heparin, direct thrombin inhibitors, hypofibrinogenemia, dysfibrinogenemia, and elevated fibrin degradation products.

Natural Anticoagulant Pathways

Antithrombin (AT)

Antithrombin is a serine protease inhibitor (serpin) that inhibits thrombin, factor Xa, factor IXa, and factor XIa. Heparin enhances antithrombin activity approximately 1000-fold by inducing a conformational change that accelerates its interaction with target proteases. Antithrombin deficiency is the most thrombogenic of the inherited thrombophilias, carrying a 10 to 50-fold increase in venous thromboembolism risk.

Protein C / Protein S Pathway

When thrombin binds thrombomodulin on the endothelial surface, its substrate specificity shifts from procoagulant to anticoagulant: the thrombin-thrombomodulin complex activates protein C. Activated protein C (APC), using protein S as a cofactor, inactivates factors Va and VIIIa, thereby shutting down thrombin generation. Factor V Leiden, the most common inherited thrombophilia, results from an R506Q mutation that renders factor Va resistant to APC cleavage. Protein C or protein S deficiency increases VTE risk, and protein C deficiency is the classic cause of warfarin-induced skin necrosis, which occurs because protein C, with its short half-life of approximately 8 hours, is depleted more rapidly than the procoagulant factors during warfarin initiation, creating a transient hypercoagulable state.

Tissue Factor Pathway Inhibitor (TFPI)

TFPI inhibits the TF-VIIa-Xa complex, thereby limiting the initiation phase of coagulation. It is primarily associated with the endothelial surface and represents an important early checkpoint against excessive coagulation activation.

Fibrinolysis

Fibrinolytic System

Tissue plasminogen activator (tPA), released from the endothelium, is the principal activator of fibrinolysis, converting the zymogen plasminogen to the active serine protease plasmin. Urokinase plasminogen activator (uPA) provides an additional activation pathway that is particularly important in extravascular fibrinolysis. Plasmin cleaves fibrin into fibrin degradation products (FDPs), including D-dimer, which is a fragment specific to cross-linked fibrin degradation. D-dimer is elevated in VTE, DIC, post-surgical states, pregnancy, and infection, and its clinical value lies primarily in its high negative predictive value for excluding VTE when the pre-test probability is low.

Fibrinolysis Inhibitors

Several physiologic inhibitors regulate the fibrinolytic system to prevent premature or excessive clot dissolution. Plasminogen activator inhibitor-1 (PAI-1) inhibits tPA and is elevated in metabolic syndrome and inflammatory states. Alpha-2 antiplasmin rapidly inactivates free plasmin in the circulation. Thrombin-activatable fibrinolysis inhibitor (TAFI), activated by the thrombin-thrombomodulin complex, removes lysine residues from fibrin, reducing plasminogen binding sites and thereby protecting the clot from premature lysis. Tranexamic acid (TXA) is a synthetic lysine analog that blocks the binding of plasminogen to fibrin and is widely used as an antifibrinolytic agent in trauma, surgery, and heavy menstrual bleeding. The CRASH-2 trial demonstrated that TXA administered within 3 hours of trauma reduces mortality, but late administration beyond 3 hours may paradoxically increase mortality.

<image>A comprehensive cell-based model of coagulation diagram showing three phases: Initiation, Amplification, and Propagation. In the Initiation phase (left panel), show tissue factor-bearing cells with TF-VIIa complex activating X→Xa and IX→IXa, with TFPI inhibiting the complex. Small amounts of thrombin generated. In the Amplification phase (center panel), show thrombin activating platelets (PAR receptors), factor V→Va, factor VIII→VIIIa (released from VWF), and factor XI→XIa on the platelet surface. In the Propagation phase (right panel), show the activated platelet surface with phosphatidylserine exposed, intrinsic tenase (IXa+VIIIa) generating Xa, prothrombinase (Xa+Va) generating the thrombin burst, and fibrinogen being cleaved to fibrin with XIIIa cross-linking. Include natural anticoagulant pathways as regulatory checkpoints: antithrombin (inhibiting thrombin and Xa), protein C/S pathway (inactivating Va and VIIIa), and TFPI. Show the fibrinolytic system at the bottom: tPA converting plasminogen to plasmin, cleaving fibrin to D-dimer/FDPs, with PAI-1 and alpha-2 antiplasmin as inhibitors. Use color coding: procoagulant factors in red, anticoagulant in blue, fibrinolytic in green. Medical textbook illustration style.</image>

Laboratory Assessment of Hemostasis

Screening Tests

The PT/INR assesses the extrinsic and common pathways, with factor VII being the most sensitive factor due to its short half-life. The aPTT evaluates the intrinsic and common pathways and is sensitive to deficiencies of factors VIII, IX, XI, and XII as well as the presence of heparin. The fibrinogen level, measured by the Clauss method, indicates significant bleeding risk when below 100 mg/dL. The platelet count provides quantitative assessment but does not evaluate platelet function. The bleeding time is a historical test that is no longer recommended due to poor sensitivity and specificity.

Mixing Studies

When the PT or aPTT is prolonged, a mixing study (1:1 mix of patient plasma with normal plasma) helps distinguish between a factor deficiency and an inhibitor. If the prolonged clotting time corrects on mixing, a factor deficiency is present, as the missing factor is supplied by the normal plasma. If the clotting time does not correct, an inhibitor is present, meaning an antibody or lupus anticoagulant neutralizes the factors in the normal plasma as well. A time-dependent inhibitor, such as a factor VIII inhibitor, may initially correct on mixing but prolong again after a 2-hour incubation at 37 degrees Celsius, and quantification requires the Bethesda assay.

Specialized Platelet Testing

The platelet function analyzer (PFA-100/200) measures closure time and serves as a screening test for von Willebrand disease and aspirin effect, though it is not useful for assessing clopidogrel responsiveness. Light transmission aggregometry (LTA) is the gold standard for platelet function assessment and uses a panel of agonists including ADP, collagen, epinephrine, arachidonic acid, and ristocetin. Absent ristocetin-induced aggregation suggests VWD or Bernard-Soulier syndrome, while absent aggregation to all agonists except ristocetin is the classic pattern of Glanzmann thrombasthenia, indicating a GPIIb/IIIa defect. Viscoelastic testing with thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provides point-of-care assessment of clot formation, strength, and fibrinolysis and is increasingly used in trauma and surgical bleeding management to guide targeted component therapy.

Thrombin Generation Assays

Calibrated automated thrombinography (CAT) measures endogenous thrombin potential (ETP) and provides a global assessment of the hemostatic system's capacity for thrombin generation. While primarily a research tool, it is becoming more clinically available and may be useful in identifying hypo- or hypercoagulable states not captured by standard PT and aPTT measurements.

Key Clinical Pearls

• The cell-based model (initiation, amplification, propagation) better explains in vivo coagulation than the traditional cascade; the traditional cascade is useful only for interpreting PT/aPTT
• Factor XII deficiency prolongs the aPTT but does NOT cause bleeding; it may paradoxically increase thrombotic risk (contact pathway involvement in pathologic thrombosis)
• A prolonged aPTT that does not correct on mixing study can be either a lupus anticoagulant (thrombotic risk) or a factor inhibitor (bleeding risk) - these are clinically opposite conditions
• D-dimer reflects cross-linked fibrin degradation and is elevated in many conditions beyond VTE; its value is primarily in EXCLUDING VTE (high negative predictive value when pre-test probability is low)
• Tranexamic acid should be given within 3 hours of trauma (CRASH-2 trial: mortality benefit only with early administration; late administration may increase mortality)
• Warfarin-induced skin necrosis results from rapid protein C depletion (shorter half-life than other vitamin K-dependent factors); bridge with heparin when initiating warfarin

References

1. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.
2. Smith SA, et al. How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326-336.
3. Konkle BA. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program. 2011;2011(1):391-396.
4. CRASH-2 collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). Lancet. 2010;376(9734):23-32.
5. Versteeg HH, et al. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327-358.

Read this lecture as Markdown